Tech Company Financing Transactions
Scioderm Funding Round
On 4/27/2013, Scioderm landed $16 million in Series A funding from Morgenthaler Ventures and Technology Partners.
Transaction Overview
Company Name
Announced On
4/27/2013
Transaction Type
Venture Equity
Amount
$16,000,000
Round
Series A
Investors
Morgenthaler Ventures (Lead Investor) (Ralph Christoffersen)
Technology Partners (Roger Quy)
Proceeds Purpose
With the proceeds from the Series A investment, Scioderm intends to advance SD-101, a topical cream with a unique mechanism of action, into clinical development through registration for the treatment of the severe skin effects seen in patients across all EB subtypes.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1007 Slater Road 170
Durham, NC 27703
USA
Durham, NC 27703
USA
Phone
Website
Email Address
Overview
The core business focus of Scioderm is the development of innovative dermatological drugs. Our strategy is to in-license or acquire early to mid-stage pharmaceutical products with the intent to develop the topical products.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Ryan
Chief Scientific Officer
Ron Nardi
VP - Operations
Willistine Lenon
Browse more venture capital transactions:
Prev: 4/27/2013: Swifto venture capital transaction
Next: 4/27/2013: Acumen Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC transactions on this site come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs